1 / 9

Influenza Vaccine Manufacturing

Influenza Vaccine Manufacturing. Industry perspective for 2013-2014 influenza vaccine supply.

ashley
Télécharger la présentation

Influenza Vaccine Manufacturing

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Influenza Vaccine Manufacturing Industry perspective for 2013-2014 influenza vaccine supply The FDA CBER requested this annual summary of information from influenza vaccine manufacturers supplying the U.S., for purposes of a general presentation to the VRBPAC. This summary has been prepared  from a variety of public sources, and was reviewed by GSK, Sanofi-Pasteur, Novartis, CSL, and MedImmune.   VRBPAC, 27 February 2013

  2. Northern Hemisphere Influenza Vaccine Strain Changes VRBPAC, 27 February 2013

  3. 2012-2013 Influenza Vaccine Production • Successful manufacturing campaign • Timely strain recommendation by VRBPAC for the 2012-13 season: • Trivalent commercial vaccines should contain two new strains • A/Victoria/361/2011 (H3N2)-like and B/Wisconsin/1/2010-like (Yamagata lineage) • Quadrivalent investigational vaccines should contain the additional B/Brisbane/60/2008-like strain (Victoria lineage) strain • Challenges • Late identification of new H3N2 strain (late flu season, H3N2 strains increasingly difficult to isolate in eggs) • At the time of the 2012 VRBPAC meeting IIV manufacturers had not received the H3N2 Victoria IIV reassortant, and LAIV manufacturer had not received the wild-type strain for reassortant production • Manufacturing seeds not available • No opportuity to evaluate/optimize vaccine strain in manufacturing processes • Manufacturing of 3rd strain started later than usual • H3N2 antigen and calibrated reagents were available later than usual • CBER commitment to providing reagents and transparency regarding timing of reagent availability facilitated planning of manufacturing activities VRBPAC, 27 February 2013

  4. Influenza Manufacturing Cycle Produce Reassortants Produce & Standardize Reagents Annual License Approval Select Vaccine Strain(s) WHO-FDA Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Produce Working Seeds (3 strains) Formulation, Fill, Packaging of Trivalent Vaccine Manufacture Strain 1 Strain Balancing Manufacture Strain 2 Strain Balancing Manufacture Strain 3 Strain Balancing Distribution

  5. Influenza Vaccine ManufacturingCritical Factors • Global timing of strain selection ensures large vaccine supply • Available time to manufacture influenza vaccine is determined by • Need to distribute & administer vaccine before the peak season • Availability of last vaccine strain • To ensure timely availability of influenza vaccine, manufacturing of one strain starts at risk before final strain composition is made • Productivity of the least productive monovalent strain determines supply quantity • Availability of Potency Test Reagents • Complex process to prepare and standardize potency reagents for new strains • Linked to global timing of strain selection for new strains • Availability of calibrated reagents determines start of influenza vaccine formulation VRBPAC, 27 February 2013

  6. Examples of Vaccine Strains under Consideration/Evaluation for 2013-2014 NH Vaccine • H1N1: A/California/7/2009-like • *A/California/7/2009 and reassortants (IIV and LAIV) • A/Christchurch/16/2010 and reassortants (IIV) • H3N2: *A/Victoria/361/2011-like • A/Texas/50/2012 and reassortants (IIV and LAIV) * Indicates most recent H1N1pdm and H3N2 vaccine strains VRBPAC, 27 February 2013

  7. Examples of Vaccine Strains under Consideration/Evaluation for 2013-2014 NH Vaccine • B Yamagata lineage: • B/Massachusetts/2/2012 and reassortants (IIV and LAIV) • B Victoria lineage (for quadrivalent vaccines): • *B/Brisbane/60/2008 and reassortants (IIV and LAIV) • B/Nevada/3/2011 and reassortants (IIV and LAIV) • B/Hong Kong/259/2010 and reassortants (IIV) • *Indicates most recent Victoria lineage vaccine strain VRBPAC, 27 February 2013

  8. Influenza Manufacturing Cycle Produce Reassortants Produce & Standardize Reagents Annual License Approval Select Vaccine Strain(s) WHO-FDA Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Produce Working Seeds (3 strains) Formulation, Fill, Packaging of Trivalent Vaccine Manufacture Strain 1 Strain Balancing Manufacture Strain 2 Strain Balancing Manufacture Strain 3 Strain Balancing Distribution

  9. Shared Responsibility of Public and Private Sectors • Timely communication of surveillance data and new candidate viruses • Timely selection of vaccine strains, considering antigenic match and growth potential • Early access of all reassortant labs (NYMC, NIBSC, CSL, MedImmune, others) to wild-type viruses for reassortant production • Opportunity for manufacturers to evaluate growth potential of candidate strains • Time for CDC to certify antigenic properties of new candidate strains • Availability of potency test reagents for new strains by May/June • Timely approval of Annual License Supplement • Lot review and release • Collaboration on key initiatives (e.g., improved SRID assay, alternative potency assays, cell culture isolates, synthetic seeds) • Information sharing during telephone conferences, chaired by ERL or WHO, between WHO CCs, ERLs, reassortant producers and manufacturers has been key in challenging situations (e.g. 3 strain changes in one season) VRBPAC, 27 February 2013

More Related